United StatesLisa WilsonInternal CommunicationsEmail: lwilson@insitecony. com
This announcement was made through the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board of Directors.
Legal Notices
This advertisement does not constitute a promotion or advertising directed to any healthcare professional or any other audience in any country in the world (including Australia, the United States and the United Kingdom). This announcement may be accompanied by forward-looking statements regarding expected long-term events, financial functions, plans, strategies or business developments. Forward-looking statements can sometimes be understood by the use of words such as “possibly,” “expects,” “intends,” “plans,” “estimates,” “anticipates,” “outlook,” “forecasts” and “guidance. ” “. Array or other similar words. Forward-looking statements involve known and unknown dangers, uncertainties and other points that could possibly cause our actual effects, degrees of activity, functionality or achievements to differ materially from any effects, degree of activity, functionality or long-term achievement expressed or implied by such forecasts. looking statements. Forward-looking statements are based on the Company’s intelligent religious assumptions about the monetary, market, regulatory and other dangers and considerations that exist. and the Company’s business and operations in the long term and there can be no assurance that any assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements would likely include, but are not limited to, statements regarding: the initiation, timing, progress and effects of Telix’s clinical and preclinical studies, as well as studies and progression of Telix. ; Telix’s ability to effectively advance, enroll and complete product applicants into clinical studies, aggregating multinational clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product commercialization activities; the commercialization of Telix’s applicant products, when they have been approved; estimates of Telix’s expenses, long-term revenues and capital requirements; The monetary functionality of Telix; progressions similar to Telix’s competition and industry; as well as the price and reimbursement of applicants for Telix products, if and after their approval. The actual effects, functionality or achievements of Telix would likely differ materially from those expressed or implied by such statements, and any differences would likely be adverse. Therefore, you should not place undue reliance on such forward-looking statements.
©2024 Telix Pharmaceuticals Limited. La Telix Pharmaceuticals and Illuccix name and logo are those of Telix Pharmaceuticals Limited and its subsidiaries (all rights reserved).